Advances in the Management of Dementia-Related Psychosis in Long-Term Care (CME/CE Webcast)

The prevalence of dementias is rising rapidly in the United States. The incidence of associated neuropsychiatric issues, including psychosis, will increase in tandem. Dementia-related psychosis places a considerable burden on affected individuals and their caregivers alike. In this educational activity, new and emerging, evidence-based strategies for evaluation, diagnosis, and treatment of dementia-related psychosis are presented, and educational tools clinicians can use in their facilities are also provided. The desired results of this activity are for clinicians working in long-term care facilities to recognize psychosis in affected persons with dementia and create person-centered, safe, and effective management plans.

This continuing medical education activity is provided by MedEdicus LLC.


This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.

Target Audience

This educational activity is intended for nurses, physicians, and caregivers in long-term care settings.

Learning Objectives

After completing this activity, participants will be better able to:

  • Identify the signs and symptoms of dementia-related psychosis in a variety of care settings
  • Apply current diagnostic criteria for dementia-related psychosis to patient scenarios specific to long-term care
  • Discuss safety and efficacy data for off-label and investigational treatments for dementia-related psychosis
  • Develop evidence-based, safe treatment plans for individuals with dementia-related psychosis in the long-term care setting
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
Course expires: 


Fay Hardison Bembry, RN, MSN, FNP-BC, PMHNP-BC
Psychiatric Mental Health Nurse Practitioner
Team Health Behavioral Health Services
Johnson City, Tennessee
George T. Grossberg, MD
Samuel W. Fordyce Professor
Director, Geriatric Psychiatry
Department of Psychiatry and Behavioral Neuroscience
Saint Louis University School of Medicine
St Louis, Missouri

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.


Fay Hardison Bembry, RN, MSN, is on the speakers bureau for ACADIA Pharmaceuticals, Inc; Avanir Pharmaceuticals, Inc; and Myriad Neuroscience.

George T. Grossberg, MD, is a consultant for ACADIA Pharmaceuticals, Inc, Avanir Pharmaceuticals, Inc, Axsome Therapeutics, Inc, Biogen Idec, BioXcel Therapeutics, Karuna Therapeutics, and Otsuka America Pharmaceutical, Inc; and is on the speakers bureau for ACADIA Pharmaceuticals, Inc.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant financial relationships.

Planners and Managers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

For Physicians:

Accreditation Statement

image MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses:

Interprofessional Joint Accreditation Statement

image In support of improving patient care, Amedco is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Credit

Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Amedco, MedEdicus LLC, or ACADIA Pharmaceuticals Inc.

This CE/CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 237

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

Clicking Register indicates that you have reviewed the CME information for this activity.

Learning Method and Medium

This educational activity consists of a webcast and six (6) study questions. The participant should, in order, read the learning objectives, complete the pretest, view the webcast, answer all questions in the posttest, and complete the evaluation. To receive credit for this activity, please complete the posttest and evaluation. This educational activity should take a maximum of 1.0 hour to complete.